Claims for Patent: 11,191,766

Summary for Patent: 11,191,766

Title:	Methods of treating pediatric cancers
Abstract:	A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.
Inventor(s):	Michael Cox, Nisha Nanda
Assignee:	Loxo Oncology Inc
Application Number:	US16/739,845
Patent Claims:	1. A method of treating a Trk-associated pediatric cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a liquid formulation comprising: a pharmaceutically acceptable salt thereof, or a combination thereof; hydroxypropyl-β-cyclodextrin present in an amount from about 13 wt. % to about 17 wt. %; sodium citrate present in an amount from about 0.7 wt. % to about 1.5 wt. %; a sweetener that includes sucrose, glycerin, sorbitol, and flavoring, wherein the sweetener is buffered with citric acid and sodium phosphate, wherein the sweetener is preserved with methylparaben and potassium sorbate, and wherein the sweetener is present in an amount from about 45 wt. % to about 55 wt. %; and a bitterness masking agent present in the liquid formulation in an amount from about 0.2 wt. % to about 0.5 wt. %; wherein: the formulation has a pH of about 2.5 to about 5.5; and the compound of formula (I), the pharmaceutically acceptable salt thereof, or the combination thereof has a concentration of about 20 mg/mL to about 30 mg/mL in the liquid formulation. 2. The method of claim 1, wherein sodium citrate includes at least one of sodium citrate monohydrate and sodium citrate dihydrate. 3. The method of claim 1, wherein sodium citrate includes sodium citrate dihydrate. 4. The method of claim 1, wherein the subject is an infant, child, or adolescent. 5. The method of claim 1, wherein the pediatric cancer is selected from the group consisting of: congenital mesoblastic nephroma, Ph-like acute lymphoblastic leukemia, infantile fibrosarcoma, pediatric high-grade glioma (HGG), diffuse intrinsic pontine gliomas (DIPGs), pediatric papillary thyroid carcinoma, soft tissue sarcoma, and spindle cell sarcoma. 6. The method of claim 1, wherein the pediatric cancer is associated with or having a dysregulation of a NTRK gene, a Trk protein, or expression, or activity, or level of the same. 7. The method of claim 6, wherein the dysregulation of a NTRK gene, a Trk protein, or expression, or activity, or level of the same is a chromosome translocation that results in the translation of a Trk fusion protein. 8. The method of claim 7, wherein the Trk fusion protein is selected from the group consisting of ETV6-NTRK3, RET/NTRK1, TPM3-NTRK1, BTBD1-NTRK3, VCL-NTRK2, AGBL4-NTRK2, LMNA-NTRK1, TFG-NTRK1, QKI-NTRK2, NACC2-NTRK2, TPR-NTRK1, RABGAP1L-NTRK1, MPRIP-NTRK1, SQSTM1-NTRK1, EML4-NTRK3, and AFAP1-NTRK2. 9. The method of claim 8, wherein the Trk fusion protein is ETV6-NTRK3. 10. The method of claim 6, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or activity of the same is one or more point mutations in the gene. 11. The method of claim 10, wherein the one or more point mutations in the gene result in (i) translation of a TrkA protein have one or more amino acid substitutions selected from the group consisting of C6773T, C7232T, C7301T, R33W, A336E, A337T, R324Q, R324W, V420M, R444Q, R444W, G517R, G517V, K538A, V573M, F589L, G595R, G667C, F598L, R649W, R649L, R682S, V683G, R702C, Q627X, Q597X, and Q633X; (ii) translation of a TrkB protein having one or more amino acid substitutions selected from the group consisting of A13T, E142K, R136H, V619M, F633L, G639R, G709C, G709A, and G709S; and/or (iii) translation of a TrkC protein having one or more amino acid substitutions selected from the group consisting of V603M, F617L, G623R, G696C, G696A, and G696S. 12. A method of treating a Trk-associated pediatric cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a liquid formulation comprising: a pharmaceutically acceptable salt thereof, or a combination thereof; hydroxypropyl-β-cyclodextrin present in an amount from about 13 wt. % to about 17 wt. %; sodium citrate dihydrate present in an amount from about 0.7 wt. % to about 1.5 wt. %; a sweetener that includes sucralose; and a flavoring agent present in an amount from about 0.01 wt. % to about 0.1 wt. %; wherein: the formulation has a pH of about 2.5 to about 5.5; and the compound of formula (I), the pharmaceutically acceptable salt thereof, or the combination thereof has a concentration of about 20 mg/mL to about 30 mg/mL in the liquid formulation. 13. The method of claim 12, wherein sodium citrate includes at least one of sodium citrate monohydrate and sodium citrate dihydrate. 14. The method of claim 12, wherein sodium citrate includes sodium citrate dihydrate. 15. The method of claim 12, wherein the subject is an infant, child, or adolescent. 16. The method of claim 12, wherein the pediatric cancer is selected from the group consisting of: congenital mesoblastic nephroma, Ph-like acute lymphoblastic leukemia, infantile fibrosarcoma, pediatric high-grade glioma (HGG), diffuse intrinsic pontine gliomas (DIPGs), pediatric papillary thyroid carcinoma, soft tissue sarcoma, and spindle cell sarcoma. 17. The method of claim 12, wherein the pediatric cancer is associated with or having a dysregulation of a NTRK gene, a Trk protein, or expression, or activity, or level of the same. 18. The method of claim 17, wherein the dysregulation of a NTRK gene, a Trk protein, or expression, or activity, or level of the same is a chromosome translocation that results in the translation of a Trk fusion protein. 19. The method of claim 18, wherein the Trk fusion protein is selected from the group consisting of ETV6-NTRK3, RET/NTRK1, TPM3-NTRK1, BTBD1-NTRK3, VCL-NTRK2, AGBL4-NTRK2, LMNA-NTRK1, TFG-NTRK1, QKI-NTRK2, NACC2-NTRK2, TPR-NTRK1, RABGAP1L-NTRK1, MPRIP-NTRK1, SQSTM1-NTRK1, EML4-NTRK3, and AFAP1-NTRK2. 20. The method of claim 19, wherein the Trk fusion protein is ETV6-NTRK3. 21. The method of claim 17, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or activity of the same is one or more point mutations in the gene. 22. The method of claim 21, wherein the one or more point mutations in the gene result in (i) translation of a TrkA protein have one or more amino acid substitutions selected from the group consisting of C6773T, C7232T, C7301T, R33W, A336E, A337T, R324Q, R324W, V420M, R444Q, R444W, G517R, G517V, K538A, V573M, F589L, G595R, G667C, F598L, R649W, R649L, R682S, V683G, R702C, Q627X, Q597X, and Q633X; (ii) translation of a TrkB protein having one or more amino acid substitutions selected from the group consisting of A13T, E142K, R136H, V619M, F633L, G639R, G709C, G709A, and G709S; and/or (iii) translation of a TrkC protein having one or more amino acid substitutions selected from the group consisting of V603M, F617L, G623R, G696C, G696A, and G696S.